Aphria (NASDAQ:APHA) Stock Rating Reaffirmed by Canaccord Genuity

Aphria (NASDAQ:APHA)‘s stock had its “hold” rating reissued by stock analysts at Canaccord Genuity in a note issued to investors on Monday, Benzinga reports.

APHA has been the topic of several other research reports. Alliance Global Partners boosted their price target on Aphria from $20.00 to $26.00 and gave the stock a “buy” rating in a research report on Thursday, April 8th. BMO Capital Markets boosted their price target on Aphria from $7.00 to $15.00 and gave the stock a “market perform” rating in a research report on Friday, January 15th. Zacks Investment Research lowered Aphria from a “hold” rating to a “strong sell” rating in a research report on Thursday, April 8th. Pi Financial lowered Aphria from a “buy” rating to a “neutral” rating in a research report on Tuesday, April 13th. Finally, Standpoint Research reaffirmed a “hold” rating and set a $18.00 price target on shares of Aphria in a research report on Thursday, April 15th. One analyst has rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $20.03.

Aphria stock opened at $13.14 on Monday. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.36 and a quick ratio of 1.17. The stock has a fifty day moving average price of $17.43 and a two-hundred day moving average price of $12.02. Aphria has a 52-week low of $2.78 and a 52-week high of $32.29. The firm has a market capitalization of $4.16 billion, a P/E ratio of -22.27 and a beta of 2.67.

Aphria (NASDAQ:APHA) last announced its earnings results on Sunday, April 11th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.04) by ($1.10). The business had revenue of $153.60 million for the quarter, compared to the consensus estimate of $172.01 million. Aphria had a negative return on equity of 2.30% and a negative net margin of 36.10%. Aphria’s revenue for the quarter was up 6.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.02 EPS. On average, equities research analysts predict that Aphria will post -0.06 EPS for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Johnson Midwest Financial LLC bought a new stake in Aphria in the 4th quarter valued at $25,000. Valeo Financial Advisors LLC bought a new stake in Aphria in the 4th quarter valued at $28,000. Berman Capital Advisors LLC bought a new stake in Aphria in the 4th quarter valued at $34,000. AlphaMark Advisors LLC boosted its stake in Aphria by 650.7% in the 4th quarter. AlphaMark Advisors LLC now owns 5,105 shares of the company’s stock valued at $35,000 after purchasing an additional 4,425 shares during the period. Finally, Liberty Wealth Management LLC bought a new stake in Aphria in the 4th quarter valued at $43,000. Institutional investors and hedge funds own 10.30% of the company’s stock.

Aphria Company Profile

Aphria Inc cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands.

Read More: How interest rates affect municipal bond prices

Analyst Recommendations for Aphria (NASDAQ:APHA)

Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.